A clinical research team is designing a study to evaluate two new therapies for major depressive disorder: a novel oral serotonin-norepinephrine reuptake inhibitor (Drug A) and a new non-invasive transcranial magnetic stimulation protocol (Device B). They randomize 800 patients with moderate-to-severe depression into four distinct groups: Drug A plus a sham device, Device B plus a placebo pill, Drug A plus Device B, and a placebo pill plus a sham device. The primary endpoint is the mean reduction in the Hamilton Depression Rating Scale (HAM-D) score at 12 weeks. Which of the following best describes the primary methodological advantage that this specific study design provides over conducting two separate, independent randomized controlled trials?
- It provides the ability to formally assess for effect modification between the pharmacological and device-based interventionsCevap
- BIt allows investigators to eliminate effect modification by controlling for one intervention as a confounding variable
- CIt simplifies the statistical analysis by allowing the use of an independent samples t-test to compare the final mean symptom scores across all four groups
- DIt ensures that the positive predictive value of the study's diagnostic criteria remains independent of the baseline disease prevalence
- EIt serves to prospectively identify significant pharmacokinetic drug-drug interactions, such as cytochrome P450 inhibition, between the two interventions